Literature DB >> 21252055

The effect of smoking on the risk of lung cancer mortality for asbestos workers in Great Britain (1971-2005).

Gillian Frost1, Andrew Darnton, Anne-Helen Harding.   

Abstract

OBJECTIVES: Workers in the asbestos industry tend to have high smoking rates compared to the general population. Both asbestos exposure and cigarette smoking are recognized risk factors for lung cancer mortality, but the exact nature of the interaction between the two remains uncertain. The aim of this study was to examine the effect of smoking and smoking cessation among asbestos workers in Great Britain (GB) and investigate the interaction between asbestos exposure and smoking.
METHODS: The study population consisted of 98 912 asbestos workers recruited into the GB Asbestos Survey from 1971, followed-up to December 2005. Poisson regression was used to estimate relative risks of lung cancer mortality associated with smoking habits of the asbestos workers and to assess whether these effects differed within various categories of asbestos exposure. The interaction between asbestos exposure and smoking was examined using the Synergy (S) and Multiplicativity (V) indices, which test the hypotheses of additive and multiplicative interaction, respectively. The proportion of lung cancers among smokers attributable to the interaction of asbestos and smoking was also estimated.
RESULTS: During 1 780 233 person-years of follow-up, there were 1878 deaths from lung cancer (12% of all deaths). Risk of lung cancer mortality increased with packs smoked per day, smoking duration, and total smoke exposure (pack-years). Asbestos workers who stopped smoking remained at increased risk of lung cancer mortality up to 40 years after smoking cessation compared to asbestos workers who never smoked. The effects of smoking and stopping smoking did not differ by duration of asbestos exposure, main occupation, age at first asbestos exposure, year of first exposure, or latency period. The interaction between asbestos exposure and smoking for asbestos workers was greater than additive [S 1.4, 95% confidence interval (CI) 1.2-1.6], and the multiplicative hypothesis could not be rejected (V 0.9, 95% CI 0.3-2.4). For those asbestos workers who smoked, an estimated 26% (95% CI 14-38%) of lung cancer deaths were attributable to the interaction of asbestos and smoking.
CONCLUSIONS: This study emphasizes the importance of smoking prevention and cessation among those who work in the asbestos industry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252055     DOI: 10.1093/annhyg/meq089

Source DB:  PubMed          Journal:  Ann Occup Hyg        ISSN: 0003-4878


  18 in total

1.  Interaction of occupational and personal risk factors in workforce health and safety.

Authors:  Paul A Schulte; Sudha Pandalai; Victoria Wulsin; HeeKyoung Chun
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

2.  miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes.

Authors:  Yong-Kui Zhang; Wang-Yu Zhu; Jian-Ying He; Dong-Dong Chen; Yan-Yan Huang; Han-Bo Le; Xiao-Guang Liu
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-22       Impact factor: 4.553

3.  Individual predictors of increased serum mesothelin in asbestos-exposed workers.

Authors:  Rosa Filiberti; Paola Marroni; Manlio Mencoboni; Virginia Mortara; Pietro Caruso; Alex Cioè; Luigi Michelazzi; Domenico F Merlo; Andrea Bruzzone; Barbara Bobbio; Lisette Del Corso; Roberto Galli; Paola Taveggia; Guglielmo Dini; Fabio Spigno
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

4.  What proportion of lung cancer in never-smokers can be attributed to known risk factors?

Authors:  Julia Sisti; Paolo Boffetta
Journal:  Int J Cancer       Date:  2012-03-27       Impact factor: 7.396

Review 5.  Assessing health risks from multiple environmental stressors: Moving from G×E to I×E.

Authors:  Cliona M McHale; Gwendolyn Osborne; Rachel Morello-Frosch; Andrew G Salmon; Martha S Sandy; Gina Solomon; Luoping Zhang; Martyn T Smith; Lauren Zeise
Journal:  Mutat Res Rev Mutat Res       Date:  2017-11-24       Impact factor: 5.657

Review 6.  Occupational exposure and lung cancer.

Authors:  Dionysios Spyratos; Paul Zarogoulidis; Konstantinos Porpodis; Kosmas Tsakiridis; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Georgios Dryllis; Anastasios Kallianos; Aggeliki Rapti; Chen Li; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 7.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

Review 8.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  Occupational exposure to asbestos and lung cancer in men: evidence from a population-based case-control study in eight Canadian provinces.

Authors:  Paul J Villeneuve; Marie-Élise Parent; Shelley A Harris; Kenneth C Johnson
Journal:  BMC Cancer       Date:  2012-12-13       Impact factor: 4.430

10.  The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005).

Authors:  G Frost
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.